Objectives: The aim of the present study was to evaluate the effects of amphotericin B (AMB) on clinical isolates of Aspergillus flavus.
Introduction
In addition to Aspergillus fumigatus, other Aspergillus species, such as Aspergillus flavus, Aspergillus terreus and Aspergillus niger, have increasingly become the causative agents of severe opportunistic infections, mainly in immunocompromised patients. 1 It has been reported that some Aspergillus species other than A. fumigatus might be less susceptible to currently used antifungal agents. Indeed, a reduced susceptibility to amphotericin B (AMB) has been described among isolates of A. flavus and A. terreus. 2 -6 In addition, the former species has been reported to be consistently more virulent than A. fumigatus. 7 -9 These two characteristics (i.e. reduced drug susceptibility along with enhanced virulence traits) makes A. flavus a species more difficult to manage than A. fumigatus. 10, 11 In this study, we investigated the effects of AMB on the outcome of experimental invasive aspergillosis caused by clinical isolates of A. flavus with variable susceptibilities to the polyene.
Methods

Isolates
Seven clinical isolates of A. flavus were utilized in this study (see Table 1 ). They were cultured from several specimens of patients suffering from haematological malignancies. Each strain represented a unique isolate # The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2013; 68: 2587 -2591 doi:10.1093/jac/dkt232 Advance Access publication 21 June 2013 from a patient. Identification to the species level was first made by conventional methods and then confirmed by molecular analysis, as described elsewhere. 3 The isolates were maintained in slopes of nutrient broth containing 10% glycerol in liquid nitrogen for subculturing. Before testing, each isolate was subcultured on Sabouraud dextrose agar to ensure viability and purity.
Drugs
AMB was used as pure powder (Sigma-Aldrich, Milan, Italy) dissolved in DMSO for in vitro studies and as a commercial preparation (Fungizone; Bristol-Myers Squibb, Latina, Italy) dissolved in 5% dextrose water for in vivo studies. Liposomal AMB (L-AMB; Gilead Sciences, Milan, Italy) was used as a commercial preparation for both in vitro and in vivo studies.
In vitro studies
Antifungal susceptibility testing was performed by a broth dilution method following the recommendations of CLSI document M38-A2. 12 The final range of drug concentrations tested was 0.03 -16 mg/L. Following incubation, MIC endpoints were determined as the lowest drug concentration that resulted in a 100% reduction in growth compared with that of the drug-free controls. As specified in the CLSI methodology, quality control was ensured by testing the following strains: Aspergillus fumigatus ATCC MYA-3626; A. flavus ATCC MYA-3631; Candida parapsilosis ATCC 22019; and Candida krusei ATCC 6258. 3, 12 Additionally, the AMB Etest (AB BIODISK, Solna, Sweden) was performed on RPMI 1640 agar plates with 2% glucose (Sigma-Aldrich) according to the manufacturer's instructions, with inoculum suspensions prepared in the same way as for the CLSI method. After 48 h of incubation, the Etest MIC was defined as the lowest drug concentration at which the border of the elliptical inhibition zone intercepted the scale on the antifungal strip. 13 -15 Each isolate was tested in triplicate by broth dilution and the Etest.
In vivo studies
CD1 female mice (20 g, 8 weeks old; Charles River Laboratories, Calco, Italy) were utilized in all in vivo studies. Mice were rendered neutropenic by intraperitoneal administration of cyclophosphamide (200 mg/kg of body weight) on days 24, +1 and +4 and every 3 days thereafter. Experiments were conducted with the approval of the University of Ancona Ethics Committee and animals were cared for in accordance with national regulations. A murine model of systemic aspergillosis was established by intravenous injection of 1×10 4 (range 0.5-3.4×10 4 ) conidia of each A. flavus isolate. Drugs were administered intravenously in a 0.2 mL final volume. AMB was given at 1 mg/kg/day. L-AMB was given at 1, 3 and 10 mg/kg/day. All drugs were initiated 6 h post-infection and were continued to day 2 post-infection (i.e. three daily doses on days 0, 1 and 2 post-infection). 16 The mice were observed twice daily until day 15 postinfection. There were 8 -10 mice in each group.
Statistical analysis
The survival studies were analysed by the log-rank test and plotted using Kaplan-Meier curves. All P values ,0.05 were considered significant. Table 1 ). Figure 1 shows survival studies for seven isolates of A. flavus. There were two isolates (# 163 and # 235) for which all drug doses were effective at prolonging the survival compared with the controls. For these isolates, the AMB MIC was ≤1.0 mg/L, regardless of the method/ drug formulation utilized for testing. There were four isolates (# 175, # 225, # 243 and # 264) for which no regimen was effective. Three of these isolates showed AMB MICs ranging from 1.0 to 2.0 mg/L, while L-AMB MICs ranged from 16 to .16 mg/L. AMB MICs obtained by the Etest for the four isolates were all ≥2.0 mg/L. Since isolate # 225 showed the lowest L-AMB MIC (0.06 mg/L) among all the isolates tested, we repeated a survival study and found identical results (Figure 1 ). For this isolate, the AMB MIC obtained by the Etest was 2.0 mg/L. There was one isolate (# 218) for which only L-AMB given at 10 mg/kg/day was effective at prolonging survival. Broth dilution yielded AMB/L-AMB MICs of 0.5 mg/L, while the Etest yielded an AMB MIC of 2.0 mg/L.
Results
AMB
Discussion
To our knowledge, this is the first study in which AMB has been tested in vivo against a considerable number of clinical isolates of A. flavus. Our study highlights several features.
First, not all clinical isolates of A. flavus should be considered resistant to AMB. Indeed, we found a wide range of MICs (0.06 to .32 mg/L). The in vitro results were greatly affected by the methodology utilized for testing. As repeatedly described in the literature, CLSI methodology (i.e. AMB tested by broth dilution) produced the narrower MIC range (0.5 -2.0 mg/L). These data reinforce the notion that this method is not able to differentiate isolates with variable susceptibility to the polyene. This fact has been demonstrated for both yeasts and mould isolates. 17 -21 To overcame this inconvenience the use of antibiotic medium 3 has been proposed, with the caveat that batch-to-batch variability of the medium should be monitored. 12 Highly controversial and Two independent survival studies yielded identical results.
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debated are the data concerning AMB MICs determined using lipid derivatives of the polyene, since these formulations after reconstitution and filtering might not be exact and could result in substantial error in the concentration of drug present in the assay, as could the release of amphotericin B from the liposomes. Some studies have shown that the use of liposomal formulations for in vitro testing yielded a broadening of MIC ranges with respect to those obtained with the pure powder form of AMB. 3,22 -25 Our results confirm this concept, having identified an L-AMB MIC range of 0.06 to .16 mg/L. Similarly, the Etest revealed variable susceptibility among the clinical isolates, with an MIC range of 1.0 to .32 mg/L. In addition, the latter method has proved to correlate better with the outcome of experimental infection. It is interesting to note that animals infected with isolates The most significant discrepancy between in vitro and in vivo data was observed for L-AMB/isolate # 225. The L-AMB MIC for this isolate was 0.06 mg/L. This value, confirmed by multiple experiments, represented the lowest MIC obtained for this series of clinical isolates. By contrast, the AMB MICs obtained by broth dilution and the Etest were 1.0 and 2.0 mg/L, respectively. This discrepancy led us to repeat the in vivo experiment, which confirmed the total inefficacy of the various regimens, including those employing high doses of the liposomal derivative. This further emphasizes that an MIC value of 2.0 mg/L characterizes an unresponsive isolate, at least in an experimental context.
Although no definitive breakpoints for AMB have been validated, several documents and case reports indicate a value of 2.0 mg/L as identifying fungal strains (yeasts or moulds) that are less susceptible to AMB therapy. 17,20,26 -30 Although limited to seven clinical isolates, our experimental data seem to indicate that this breakpoint is also suitable for characterizing the susceptibility/resistance of A. flavus.
In conclusion, our data indicate that not all clinical isolates of A. flavus are resistant to AMB. The in vitro method that best correlates with the experimental infection is the Etest. Finally, a clinical isolate showing an MIC ≥2.0 mg/L may be reasonably considered resistant in vivo to any dose/formulation of the polyene. Clearly, further studies are needed to corroborate these findings.
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